TW201504224A - 新穎吲哚及吡咯化合物,其製備方法及含有其之醫藥組合物 - Google Patents

新穎吲哚及吡咯化合物,其製備方法及含有其之醫藥組合物 Download PDF

Info

Publication number
TW201504224A
TW201504224A TW103125162A TW103125162A TW201504224A TW 201504224 A TW201504224 A TW 201504224A TW 103125162 A TW103125162 A TW 103125162A TW 103125162 A TW103125162 A TW 103125162A TW 201504224 A TW201504224 A TW 201504224A
Authority
TW
Taiwan
Prior art keywords
methyl
group
compound
phenyl
formula
Prior art date
Application number
TW103125162A
Other languages
English (en)
Chinese (zh)
Inventor
派屈克 卡薩拉
泰瑞 勒迪古荷
尚 麥可 海琳
傑若姆 畢諾特 史塔克
雅諾 樂提倫
古洛姆 德南度爾
奧莉薇 居內斯特
詹母士 愛德華 保羅 德維森
詹母士 布魯基 莫瑞
宜 傑 陳
克萊爾 瓦穆斯理
克理斯多夫 約翰 葛拉漢
史都華 雷
丹尼爾 麥多克斯
賽門 貝多弗
Original Assignee
施維雅藥廠
佛納利斯(R&D)股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 施維雅藥廠, 佛納利斯(R&D)股份有限公司 filed Critical 施維雅藥廠
Publication of TW201504224A publication Critical patent/TW201504224A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
TW103125162A 2013-07-23 2014-07-22 新穎吲哚及吡咯化合物,其製備方法及含有其之醫藥組合物 TW201504224A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1357277A FR3008978A1 (fr) 2013-07-23 2013-07-23 "nouveaux derives d'indole et de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent"

Publications (1)

Publication Number Publication Date
TW201504224A true TW201504224A (zh) 2015-02-01

Family

ID=49911607

Family Applications (1)

Application Number Title Priority Date Filing Date
TW103125162A TW201504224A (zh) 2013-07-23 2014-07-22 新穎吲哚及吡咯化合物,其製備方法及含有其之醫藥組合物

Country Status (31)

Country Link
US (2) US9765056B2 (enExample)
EP (2) EP3027602B1 (enExample)
JP (1) JP6458028B2 (enExample)
KR (1) KR102337149B1 (enExample)
CN (1) CN105408321B (enExample)
AR (1) AR099914A1 (enExample)
AU (1) AU2014294866B2 (enExample)
BR (1) BR112016001333B1 (enExample)
CA (1) CA2917965C (enExample)
CY (1) CY1120475T1 (enExample)
DK (1) DK3027602T3 (enExample)
EA (1) EA028609B1 (enExample)
ES (1) ES2687475T3 (enExample)
FR (1) FR3008978A1 (enExample)
HK (1) HK1218753A1 (enExample)
HR (1) HRP20181333T1 (enExample)
HU (1) HUE039507T2 (enExample)
LT (1) LT3027602T (enExample)
MX (1) MX364479B (enExample)
NZ (1) NZ715847A (enExample)
PL (1) PL3027602T3 (enExample)
PT (1) PT3027602T (enExample)
RS (1) RS57545B1 (enExample)
RU (1) RU2693404C2 (enExample)
SG (1) SG11201600004SA (enExample)
SI (1) SI3027602T1 (enExample)
TW (1) TW201504224A (enExample)
UA (1) UA117020C2 (enExample)
UY (1) UY35653A (enExample)
WO (1) WO2015011396A1 (enExample)
ZA (1) ZA201600415B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105237509A (zh) * 2015-11-20 2016-01-13 江苏瑞邦农药厂有限公司 一种2,2-二氟-1,3-苯并二恶茂的合成方法
CN121974842A (zh) 2016-05-10 2026-05-05 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
CN109562113A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的螺环降解决定子体
CN109562107A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
JP6928096B2 (ja) 2017-01-10 2021-09-01 イーティーエイチ・チューリッヒ 細胞保護化合物及びそれらの使用
WO2018181866A1 (ja) 2017-03-31 2018-10-04 国立大学法人東京大学 ノロウイルス抗体
EP4717317A3 (en) 2017-06-20 2026-06-03 C4 Therapeutics, Inc. N/o-linked degrons and degronimers for protein degradation
CN108409580A (zh) * 2018-02-01 2018-08-17 浙江工业大学 一种苄胺类化合物的合成方法
EP3897631A4 (en) 2018-12-20 2022-11-23 C4 Therapeutics, Inc. TARGETED PROTEIN BREAKDOWN
KR20230160303A (ko) * 2021-03-24 2023-11-23 르 라보레또레 쎄르비에르 5-{5-클로로-2-[(3s)-3-[(모르폴린-4-일)메틸]-3,4-디하이드로이소퀴놀린-2(1h)-카르보닐]페닐}-1,2-디메틸-1h-피롤-3-카르복실산 유도체의 신규한 합성 방법 및 약학적 화합물의 생산을 위한 이의 용도
IL317101A (en) 2022-05-20 2025-01-01 Novartis Ag Antibody-drug conjugates of anticancer compounds and methods of using them
AR134424A1 (es) 2023-11-22 2026-01-14 Novartis Ag Conjugados de anticuerpo anti-cd7-fármaco y métodos de uso de los mismos
UY40985A (es) 2023-11-22 2025-06-30 Servier Lab Conjugados de anticuerpo anti-cd74-fármaco y métodos de uso de los mismos

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1675832B1 (en) 2003-10-24 2008-02-20 Glaxo Group Limited Heterocyclyl compounds
TW200533398A (en) * 2004-03-29 2005-10-16 Bristol Myers Squibb Co Novel therapeutic agents for the treatment of migraine
BRPI0514504A (pt) * 2004-08-20 2008-06-10 Univ Michigan pequenas moléculas inibidoras de membros da famìlia bcl-2 anti-apoptóticos e os usos das mesmas
GB0522908D0 (en) 2005-11-10 2005-12-21 Merck Sharp & Dohme Therapeutic agents
CN103732589B (zh) * 2011-05-25 2016-03-30 百时美施贵宝公司 可用作抗细胞凋亡bcl抑制剂的取代的磺酰胺
CA2859873A1 (en) * 2011-12-23 2013-06-27 Novartis Ag Compounds for inhibiting the interaction of bcl2 with binding partners
AU2012355613A1 (en) * 2011-12-23 2014-07-17 Novartis Ag Compounds for inhibiting the interaction of BCL2 with binding partners
EA201491265A1 (ru) * 2011-12-23 2014-11-28 Новартис Аг Соединения для ингибирования взаимодействия bcl-2 с партнерами по связыванию
AU2012355623A1 (en) * 2011-12-23 2014-07-17 Novartis Ag Compounds for inhibiting the interaction of BCL2 with binding partners
AU2012355624A1 (en) * 2011-12-23 2014-07-17 Novartis Ag Compounds for inhibiting the interaction of BCL2 with binding partners
FR2986002B1 (fr) * 2012-01-24 2014-02-21 Servier Lab Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
PL3027602T3 (pl) 2018-10-31
US9765056B2 (en) 2017-09-19
UA117020C2 (uk) 2018-06-11
AU2014294866A1 (en) 2016-02-04
SG11201600004SA (en) 2016-02-26
AU2014294866B2 (en) 2018-09-27
AR099914A1 (es) 2016-08-31
EP3027602A1 (fr) 2016-06-08
EA201600121A1 (ru) 2016-07-29
CA2917965C (fr) 2018-03-06
US10662173B2 (en) 2020-05-26
WO2015011396A1 (fr) 2015-01-29
LT3027602T (lt) 2018-07-25
DK3027602T3 (en) 2018-09-24
US20170342051A1 (en) 2017-11-30
MX364479B (es) 2019-04-29
JP2016531108A (ja) 2016-10-06
CN105408321A (zh) 2016-03-16
HRP20181333T1 (hr) 2018-10-19
KR102337149B1 (ko) 2021-12-07
KR20160034384A (ko) 2016-03-29
SI3027602T1 (en) 2018-08-31
RS57545B1 (sr) 2018-10-31
JP6458028B2 (ja) 2019-01-23
FR3008978A1 (fr) 2015-01-30
CN105408321B (zh) 2019-03-08
EA028609B1 (ru) 2017-12-29
CA2917965A1 (fr) 2015-01-29
BR112016001333B1 (pt) 2022-03-03
NZ715847A (en) 2019-06-28
EP3027602B1 (fr) 2018-06-13
RU2693404C2 (ru) 2019-07-02
ES2687475T3 (es) 2018-10-25
MX2016000900A (es) 2016-05-05
PT3027602T (pt) 2018-07-23
CY1120475T1 (el) 2019-07-10
RU2016106002A (ru) 2017-08-30
US20160152599A1 (en) 2016-06-02
UY35653A (es) 2015-02-27
HUE039507T2 (hu) 2019-01-28
ZA201600415B (en) 2017-03-29
EP3168217A1 (fr) 2017-05-17
HK1218753A1 (zh) 2017-03-10
RU2016106002A3 (enExample) 2018-03-19
BR112016001333A2 (enExample) 2017-07-25

Similar Documents

Publication Publication Date Title
US10662173B2 (en) Indole and pyrrole compounds, a process for their preparation and pharmaceutical compositions containing them
TWI549948B (zh) 新穎吡咯化合物,其製備方法及包含其之醫藥組合物
CN104341451B (zh) 新磷酸酯化合物、其制备方法及含有它们的药物组合物
JP6469567B2 (ja) Egfr発動性がんの細胞増殖阻害用化合物
KR102008431B1 (ko) 이소인돌린 또는 이소퀴놀린 화합물, 이들의 제조 방법 및 이들을 함유하는 약학적 조성물
KR20190113799A (ko) 퀴나졸린 화합물
CN105228985A (zh) 3,4-二氢异喹啉-2(1h)-基化合物
CN109311888A (zh) 新的哌啶基衍生物,其制备方法和含有它们的药物组合物